drugset / Trial / NCT03149211
To Investigate the Efficacy and Safety of UB-421 Monotherapy in HIV-1 Infected Adults
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this phase III study is to evaluate the efficacy, safety and tolerability of UB-421 monotherapy in suppressing viral rebound in HIV-1 infected adults undergoing antiretroviral treatment interruption.
Timeline
- Start
- 2025-04-01
- Primary completion
- 2025-12-31
- Completion
- 2025-12-31
Outcome
Outcome not reported
Stopped: “project adjustment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SEMZUVOLIMAB | Protein / enzyme biologic | 25 mg/kg | Intravenous |